XML 115 R90.htm IDEA: XBRL DOCUMENT
v3.25.3

Subsequent Events (Details) $ in Millions |  |  |  |  |  | 1 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Nov. 20, 2025 USD ($) | Oct. 17, 2025 USD ($) program | Aug. 13, 2025 USD ($) | Feb. 24, 2025 USD ($) | Feb. 14, 2025 USD ($) | Aug. 31, 2025 USD ($) | Nov. 25, 2024 USD ($) program
Sarepta | Sarepta Collaboration Agreement |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Upfront payment |  |  | $ 50.0 | $ 500.0 | $ 500.0 | $ 50.0 |
Number of collaboration programs | program |  |  |  |  |  |  | 13
Development milestone payments |  |  |  |  |  | $ 100.0 |
Sarepta | Sarepta Collaboration Agreement | Minimum |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Sales-related milestone payments |  |  |  |  |  |  | $ 500.0
Sarepta | Sarepta Collaboration Agreement | Maximum |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Sales-related milestone payments |  |  |  |  |  |  | $ 700.0
Subsequent Event | Novartis | Novartis Collaboration Agreement |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Upfront payment |  | $ 200.0 |  |  |  |  |
Payment receivable upon target nomination |  | $ 30.0 |  |  |  |  |
Number of collaboration programs | program |  | 4 |  |  |  |  |
Subsequent Event | Novartis | Novartis Collaboration Agreement | Minimum |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Development milestone payments |  | $ 175.0 |  |  |  |  |
Sales-related milestone payments |  | 285.0 |  |  |  |  |
Subsequent Event | Novartis | Novartis Collaboration Agreement | Maximum |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Development milestone payments |  | 245.0 |  |  |  |  |
Sales-related milestone payments |  | $ 370.0 |  |  |  |  |
Subsequent Event | Sarepta | Sarepta Collaboration Agreement |  |  |  |  |  |  |
Subsequent Event [Line Items] |  |  |  |  |  |  |
Development milestone payments | $ 200.0 |  |  |  |  |  |

X
- Definition Development Milestone Payments + References No definition available. + Details
Name: | arwr_DevelopmentMilestonePayments
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number Of Collaboration Programs + References No definition available. + Details
Name: | arwr_NumberOfCollaborationPrograms
Namespace Prefix: | arwr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payment Receivable In Collaboration Arrangements Upon Target Nomination + References No definition available. + Details
Name: | arwr_PaymentReceivableInCollaborationArrangementsUponTargetNomination
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Proceeds From Collaboration Arrangements + References No definition available. + Details
Name: | arwr_ProceedsFromCollaborationArrangements
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales-related milestone payments. + References No definition available. + Details
Name: | arwr_SalesRelatedMilestonePayments
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=arwr_SareptaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_SareptaCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arwr_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_NovartisCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |